Join to View Full Profile
12902 Usf Magnolia DrTampa, FL 33612
Phone+1 703-517-0491
Dr. Faramand is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2016 - 2019
University of MarylandResidency, Internal Medicine, 2012 - 2015
Virginia Commonwealth University School of MedicineClass of 2012
Certifications & Licensure
FL State Medical License 2016 - 2026
MD State Medical License 2015 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Start of enrollment: 2022 Jun 21
Roles: Contact
- A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL Start of enrollment: 2022 Jan 14
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Body Composition Assessment Provides Prognostic Information in Patients With Cancer Affected by Chronic Graft vs. Host Disease.Asmita Mishra, Ram Thapa, Kevin Bigam, Martine Extermann, Rawan Faramand
Journal of Cachexia, Sarcopenia and Muscle. 2025-04-01 - Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy.Hannah Lust, Liora M Schultz, Soyang Kwon, Gregory W Roloff, Ibrahim Aldoss
Blood Advances. 2025-03-24 - Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL.Rawan G Faramand, Frederick L Locke
Nature Reviews. Clinical Oncology. 2025-03-01
Abstracts/Posters
- Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Revi...Rawan Faramand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in LymphomaRawan Faramand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell TherapyRawan Faramand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
- Moffitt Researchers Identify Factors to Predict Severe Toxicities in CAR T PatientsJuly 15th, 2020
Risk Stratification Can Predict Outcomes for CAR T-cell Therapy in LymphomaFebruary 16th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
